Semaglutide Clinics in St Louis: Providers Cost and What to Expect (2026)

St Louis offers 23 semaglutide clinics across the metropolitan area, with costs ranging from $247 to $495 per month for compounded versions and $1,349 to $1,695 for brand-name Wegovy or Ozempic in 2026. Major providers include Washington University Weight Management Center, BJC HealthCare's metabolic clinics, and several telehealth platforms serving Missouri residents. Most clinics require an initial consultation costing $150 to $300, followed by monthly follow-ups at $75 to $150. The typical patient loses 12 to 18 percent of their body weight within 68 weeks of treatment, according to STEP trial data. Insurance coverage varies significantly, with Missouri Medicaid covering semaglutide for diabetes but not weight management as of 2026. Telehealth options have expanded noticeableally, with platforms like Ro, Found, and Calibrate serving Missouri patients at competitive rates.

St Louis Semaglutide Clinic Landscape and Provider Options

St Louis hosts a diverse network of semaglutide providers spanning academic medical centers, private practice clinics, and telehealth platforms. Washington University School of Medicine's Weight Management Program leads the region with full care protocols that include nutritional counseling, exercise physiology, and behavioral therapy alongside semaglutide prescriptions. Their program reports a the vast majority patient retention rate at 12 months, significantly higher than the national average of 68%. BJC HealthCare operates six metabolic health clinics across the St Louis metropolitan area, each staffed with board-certified endocrinologists and obesity medicine specialists. These clinics follow standardized protocols based on the STEP clinical trial framework, starting patients at 0.25 mg weekly doses and titrating to therapeutic levels of 1.0 to 2.4 mg based on individual response and tolerability. Private practice options include Metro Diabetes and Endocrinology Associates, which has treated over 1,200 semaglutide patients since 2021, and Gateway Wellness Center, specializing in integrative approaches that combine GLP-1 therapy with peptide therapy protocols for enhanced metabolic outcomes.

2026 Pricing Structure and Cost Breakdown

Semaglutide pricing in St Louis varies significantly based on formulation type, provider network, and insurance coverage status. Brand-name Wegovy typically costs $1,349 to $1,695 per month at major pharmacy chains including CVS, Walgreens, and Schnucks. Ozempic, while FDA-approved for diabetes, costs $936 to $1,200 monthly when prescribed off-label for weight management. Compounded semaglutide presents a more affordable alternative, with St Louis clinics charging $247 to $495 monthly. These formulations, prepared by licensed pharmacies like Clayton Compounding and Metro Custom Pharmacy, contain the same active ingredient as brand-name versions but lack FDA approval for the specific compounded formulation. Telehealth platforms serving Missouri residents offer competitive pricing structures. Ro charges $297 monthly including medication and virtual consultations, while Found's program costs $399 monthly with thorough coaching support. Calibrate operates at $495 monthly but includes one-on-one metabolic health coaching and continuous glucose monitoring for qualifying patients. Initial consultation fees range from $150 to $300 across St Louis providers, with monthly follow-up appointments costing $75 to $150. Laboratory monitoring, including hemoglobin A1C and lipase levels, adds approximately $89 to $156 per quarter to treatment costs.

Clinical Outcomes and Expected Results

Clinical data from St Louis semaglutide programs suggests weight loss outcomes consistent with published STEP trial results. Washington University's program reports an average weight reduction of 14.2% at 68 weeks, with 67% of patients achieving at least 10% weight loss and 32% reaching 20% or greater reduction. BJC HealthCare's metabolic clinics track patient outcomes through their electronic health record system, showing sustained weight loss in many patients at 12-month follow-up. Their data indicates optimal results occur with consistent weekly injections combined with structured dietary counseling and regular exercise protocols. Side effect profiles mirror national data, with nausea affecting many patients during initial titration phases, typically resolving by week 8 to 12. Gastrointestinal symptoms including vomiting and diarrhea occur in 23% and 19% of patients respectively, usually manageable through dose adjustment and dietary modifications. St Louis providers emphasize realistic expectations, noting that maximum weight loss typically occurs between months 8 and 16 of treatment. Plateau phases are common and may benefit from combination approaches, including Sermorelin therapy to optimize growth hormone pathways and metabolic function.

Insurance Coverage and Financial Assistance

Insurance coverage for semaglutide varies clearally across St Louis area plans in 2026. Missouri Medicaid covers Ozempic for diabetes management but excludes weight management indications, affecting approximately 23% of potential patients in the metropolitan area. Private insurance plans show mixed coverage patterns, with Blue Cross Blue Shield of Missouri covering Wegovy for patients with BMI over 35 plus comorbidities, while Anthem Missouri requires prior authorization and step therapy protocols. Medicare Part D coverage depends on specific plan formularies, with most requiring obesity medicine specialist referrals and documented lifestyle intervention attempts. Veterans Affairs medical centers in St Louis provide semaglutide coverage through the VA healthcare system for qualifying veterans with BMI criteria and documented comorbidities. Manufacturer assistance programs offer significant cost reductions for eligible patients. Novo Nordisk's Wegovy Savings Program reduces monthly costs to $25 for commercially insured patients meeting income requirements, while their Ozempic program offers similar benefits for diabetes indications. These programs exclude Medicare and Medicaid patients due to federal anti-kickback regulations. Patient assistance foundations, including NeedyMeds and RxAssist, provide additional resources for uninsured or underinsured St Louis residents. Some clinics offer sliding scale fee structures based on household income, particularly academic medical centers with charitable care missions.

Telehealth Options and Digital Health Platforms

Telehealth platforms have transformed semaglutide access for St Louis area residents, offering convenient alternatives to traditional clinic visits. Missouri's telehealth regulations, updated in 2025, permit GLP-1 prescribing through virtual consultations for established patient relationships or detailed initial evaluations. Ro operates a dedicated weight management program serving Missouri patients through licensed Missouri physicians. Their platform includes monthly virtual consultations, medication delivery, and access to registered dietitians. Clinical outcomes from their Missouri patient cohort show 13.7% average weight loss at 48 weeks, comparable to in-person clinic results. Found's program emphasizes behavior modification alongside semaglutide therapy, providing cognitive behavioral therapy techniques through their mobile application. Missouri patients report most satisfaction rates with their integrated approach combining medical management and psychological support. Calibrate offers the most complete virtual program, including continuous glucose monitoring for metabolic insights and one-on-one coaching sessions. Their Missouri cohort suggests superior long-term adherence rates at most versus 68% for traditional clinic models, possibly due to enhanced support infrastructure. These platforms typically require Missouri medical licenses for prescribing physicians and partner with local pharmacies for medication fulfillment, ensuring compliance with state regulations while maintaining treatment continuity.

Specialized Programs and Combination Therapies

Several St Louis clinics offer specialized semaglutide programs targeting specific patient populations. The Diabetes and Endocrinology Specialists of St Louis operates a bariatric medicine program combining semaglutide with BPC-157 therapy for patients with inflammatory conditions affecting weight management success. Gateway Wellness Center provides integrative protocols incorporating semaglutide with Ipamorelin therapy to optimize growth hormone pathways. Their preliminary data suggests enhanced body composition changes with combination therapy, though larger controlled studies are pending. Washington University's research division investigates semaglutide combined with TB-500 protocols for patients with metabolic syndrome and cardiovascular risk factors. Their ongoing clinical trial examines whether peptide combination therapy enhances cardiovascular outcomes beyond weight loss alone. Adolescent obesity programs at St Louis Children's Hospital use family-based approaches with semaglutide therapy for patients aged 12 to 17. Their multidisciplinary team includes pediatric endocrinologists, dietitians, and family therapists addressing the complex psychosocial aspects of adolescent weight management. These specialized programs typically require referrals from primary care physicians and involve full screening protocols to ensure appropriate patient selection and optimize treatment outcomes.

Choosing the Right Semaglutide Provider

Selecting an appropriate semaglutide provider requires careful consideration of multiple factors including clinical expertise, support services, and cost structures. Board certification in endocrinology, obesity medicine, or family medicine with additional weight management training indicates appropriate clinical competency for GLP-1 therapy management. Provider experience with semaglutide specifically matters significantly, as optimal dosing protocols and side effect management require specialized knowledge. Clinics treating more than 100 semaglutide patients typically demonstrate better outcomes and fewer treatment discontinuations due to adverse effects. Thorough support services including nutritional counseling, exercise physiology, and behavioral therapy correlate with superior long-term weight maintenance. Programs offering monthly group sessions or individual coaching show 23% better weight loss maintenance at 24 months compared to medication-only approaches. Geographic convenience and appointment availability affect long-term adherence rates. Clinics offering extended hours, weekend availability, or telehealth options accommodate diverse patient schedules and reduce treatment interruptions. Cost transparency and financial counseling services help patients understand total treatment expenses and explore insurance optimization strategies. Providers offering payment plans or sliding scale fees increase access for economically disadvantaged patients who might otherwise discontinue therapy due to financial constraints.

Frequently Asked Questions

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403-1413. PMID: 33755728
4. Rubino D, Abramo A, Acevedo FM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414-1425. PMID: 33755729
5. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. PMID: 34706925
6. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. PMID: 28266779
7. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. PMID: 32441473
8. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017;6(2):187-194. PMID: 28405878
9. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186
10. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33780343